| Full description or abstract |
Fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) is a rare yet highly lethal kidney cancer. To deepen understanding of FH-deficient RCC, the authors conduct a comprehensive integrated genomic study. The authors analyze the association of FH alteration patterns with tumor heterogeneity and develop a CpG site-specific methylation signature for precise identification of FH-deficient RCC. Transcriptomic analysis unveils three distinctive molecular subtypes characterized by enrichment of immune/Angiogenic/Stromal (C1), WNT/Notch/MAPK (C2), and proliferation/stemness (C3) pathways, respectively. Tumors in C1 derive the most substantial survival benefit from a combination of immune checkpoint blockade (ICB) and anti-angiogenic therapy. Tumors in C2 display moderate response to this therapeutic approach. In contrast, tumors in C3 exhibit an unfavorable response to anti-angiogenic monotherapy and its combination with ICB. These findings contribute to a profound understanding of the aggressive nature of FH-deficient RCC, offering insights into potential precision medicine approaches for disease management. |
| Source publication |
Pubmed 40355427 Authors: Zhang X,Zhao J,Yin X,Liang J,Wang Y,Zheng L,Tan P,Lin Y,Xu N,Zhu S,Chen J,Zhao J,Hu X,Pan X,Nie L,Zhang M,Chen Y,Zhang Y,Liu H,Dai J,Wang Z,Liu H,Ni Y,Rupp NJ,Moch H,Sheng X,Gong K,Liu X,Chen Z,He Z,Wang Y,Xu L,Liu M,Zhou H,Tang B,Huang R,Wei Q,Li X,Liu J,Yao J,Liao B,Liu Z,Shen P,Chen N,Zeng H,Sun G |
